Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $61 million for the full year 2021, compared to a net loss of $43 million in 2020 [19] - For Q4 2021, the GAAP net loss was $22 million, compared to a net loss of $19 million for the same period in 2020 [19] - Revenue for the year ended December 31, 2021, was $1.3 million, with a gross loss of $1.5 million [19][20] - Non-GAAP net loss for the full year 2021 was $39.2 million, compared to $18.9 million in 2020 [25] Business Line Data and Key Metrics Changes - Revenue from radiology services for Q4 2021 was $1 million, with a gross profit of $0.0 million on a GAAP basis and a gross profit of $0.4 million on a non-GAAP basis, representing a gross profit margin of approximately 40% [20] - Revenue from licensing of AI applications for Q4 2021 was $0.3 million, with a gross loss of $1.5 million on a GAAP basis [21] Market Data and Key Metrics Changes - The company signed 11 MSaaS agreements for the global deployment of 6,500 units of the Nanox.ARC multi-source system across various territories, including Africa, Central America, and Europe [15] Company Strategy and Development Direction - The company aims to streamline commercialization through strategic acquisitions, including Zebra Medical Vision (now Nanox.AI), USARAD Holdings, and MDW LLC, to enhance healthcare access and affordability [9][10] - The leadership team of Nanox.AI has been strengthened with the appointment of Pini Ben Elazar as General Manager [12] - The company is focused on establishing production capabilities for the Nanox.ARC system and enhancing regulatory pathways [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about ongoing communication with the FDA regarding the Nanox.ARC system and expects thoughtful improvements based on FDA feedback [7][8] - The company anticipates being in full production of the Nanox.ARC system by mid-2022, which is crucial given current global chip supply shortages [17] Other Important Information - As of December 31, 2021, the company had cash equivalents and marketable securities of $156.6 million and $3.8 million in loans from banks [27] - The company ended the year with approximately 51.8 million shares outstanding, an increase from 46.1 million shares at the end of 2020, primarily due to acquisitions [28] Q&A Session Summary Question: What is the update expectation on approval or clearance for the multisource? - Management indicated that they do not expect the FDA response to take the full 75 days and are hopeful for a quicker response based on ongoing discussions [35][36] Question: What are the annualized revenue run rates and growth rates for Nanox.AI and USARAD segments for FY 2022? - Expected annual revenue for USARAD is around $8 million to $9 million, while for the AI segment, it is projected to be $3 million to $4 million [41] Question: What was the litigation expense in the fourth quarter? - The litigation expense related to the SEC probe and class action was $455,000 for the quarter [47] Question: Can you provide a sense of the size of the integrated healthcare organization? - The organization is among the top 25 in the U.S., indicating a significant size and influence in the healthcare sector [52] Question: What is the status of the production and delivery commitments for 2022? - Management confirmed that they have ordered necessary components for assembly and expect to produce hundreds of machines quarterly [48]

Revenue Performance - Revenue for Q4 2021 was $1.3 million, compared to $0 for Q4 2020, with a non-GAAP gross profit of $0.2 million[4] - The company reported a revenue of $1.304 million for the year ended December 31, 2021, compared to $0 for the previous two years[35] Net Loss and Expenses - The company reported a net loss of $22.0 million for Q4 2021, an increase from a net loss of $19.0 million in Q4 2020, primarily due to merger-related expenses[5] - The non-GAAP net loss applicable to ordinary shares for Q4 2021 was $15.0 million, compared to $8.4 million in Q4 2020[9] - The company reported a net loss of $61.798 million for 2021, compared to a net loss of $43.815 million in 2020, which is a 41% increase[35] - The non-GAAP net loss attributable to ordinary shares for 2021 was $39.124 million, compared to $18.902 million in 2020, reflecting a 106% increase[37] Research and Development - Research and development expenses for Q4 2021 were $6.4 million, up from $3.0 million in Q4 2020, driven by the merger and increased R&D headcount[6] - Research and development expenses rose to $17.122 million in 2021, up from $9.210 million in 2020, indicating a 85% increase[35] General and Administrative Expenses - General and administrative expenses increased to $10.9 million in Q4 2021 from $8.1 million in Q4 2020, largely due to merger-related costs and legal fees[8] Cash and Assets - The company had $88.7 million in cash and cash equivalents as of December 31, 2021, down from $213.5 million a year earlier[12] - Cash and cash equivalents decreased significantly to $66.645 million in 2021 from $213.468 million in 2020, a decline of 69%[33] - The company's total assets increased to $363.170 million in 2021 from $236.149 million in 2020, representing a growth of 54%[33] Liabilities - Total current assets were $94.9 million and total current liabilities were $52.8 million, resulting in working capital of $42.1 million[12] - The total liabilities rose to $71.022 million in 2021, compared to $5.403 million in 2020, marking a substantial increase[33] Shareholder Information - The weighted average number of ordinary shares increased to 48.216 million in 2021 from 35.654 million in 2020, a rise of 35%[37] Future Outlook - The American Medical Association issued a new CPT code for quantitative CT tissue characterization, effective July 2022, which may enhance future revenue opportunities[3] - The company is focused on the development and commercialization of its X-ray source technology and the Nanox.ARC, with expectations for future growth and market acceptance[25]

Nano-X Imaging Ltd. (NASDAQ:NNOX) Q3 2021 Earnings Conference Call November 17, 2021 ET Company Participants Ran Poliakine ??? Chairman of the Board and Chief Executive Officer Mike Cavanaugh ??? Investor Relations Erez Meltzer ??? Executive Board Member and incoming Chief Executive Officer Ran Daniel ??? Chief Financial Officer Conference Call Participants Jeffrey Cohen ??? Ladenburg Thalmann Suraj Kalia ??? Oppenheimer Ravi Misra ??? Berenberg Capital Rahul Rakhit ??? LifeSci Capital Operator Thank you fo ...

Exhibit 99.1 NANO-X IMAGING LTD The Communications Center Neve Ilan, Israel 9085000 Telephone: 972 2 5360360 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on November 4, 2021 To our Shareholders: You are invited to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd ("we" or the "Company") to be held at the Company's offices at The Communications Center, Neve Ilan, Israel on November 4, 2021 at 15:00 Israeli time (9:00 am EST), and thereafter as it may be adjourned from time to tim ...

Nano-X Imaging Ltd (NASDAQ:NNOX) Q2 2021 Results Conference Call August 10, 2021 8:30 AM ET Company Participants Bob Yedid - IR Ran Poliakine - CEO Itzhak Maayan - CFO Conference Call Participants Steve Halper - Cantor Jeffrey Cohen - Ladenburg Suraj Kalia - Oppenheimer & Company Ravi Misra - Berenberg Rahul Rakhit - LifeSci Capital Operator Thank you for standing by. This is the conference operator. Welcome to the Nano-X Imaging Second Quarter 2021 Earnings Call. As a reminder, all participants are in a li ...

Nano-X Imaging Ltd (NASDAQ:NNOX) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET Company Participants Glenn Garmont - IR Rand Poliakine - CEO Itzhak Maayan - CFO Conference Call Participants Kyle Mikson - Cantor Fitzgerald Ravi Misra - Berenberg Capital Markets Jeffrey Cohen - Ladenburg Thalman Suraj Kalia - Oppenheimer Rahul Rakhit - LifeSci Capital Operator Greetings, and welcome to Nano-X Imaging Ltd's First Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Nano-X Imaging Ltd. (NASDAQ:NNOX) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET Company Participants Bob Yedid ??? LifeSci Advisors Rand Poliakine ??? Chief Executive Officer Itzhak Maayan ??? Chief Financial Officer Conference Call Participants Steve Halper ??? Cantor Fitzgerald Ravi Misra ??? Berenberg Suraj Kalia ??? Oppenheimer Rahul Rakhit ??? LifeSci Capital Operator Greetings, and welcome to Nano-X Imaging Ltd. Fourth Quarter and Full Year 2020 Earnings Call. At this time, all participant ...